19 results
8-K
EX-99.6
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
includes guidance addressing resuming normal drug and biologics manufacturing operations; manufacturing, supply chain and inspections; and statistical
8-K
EX-99.5
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
operations; manufacturing, supply chain, and inspections; and statistical considerations for clinical trials during the COVID-19 public health emergency … , and to perform quality control and testing. If either Kineta or any third-party in the supply chain for materials used in the production of Kineta’s product
424B3
cmftb7rftx p19e
10 Nov 22
Prospectus supplement
4:21pm
8-K
EX-10.1
jkdhg d8i4
4 Mar 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-99.1
sz2tggymigi2hvj
15 May 20
Proteostasis Therapeutics Reports First Quarter 2020 Financial Results
4:11pm
- Prev
- 1
- Next